TY - JOUR T1 - A magnetic bead immunoassay to detect human IgG reactive to SARS-CoV-2 Spike S1 RBD produced in <em>Escherichia coli</em> JF - medRxiv DO - 10.1101/2021.12.22.21268286 SP - 2021.12.22.21268286 AU - Marcelo S. Conzentino AU - Ana C. A. Gonçalves AU - Nigela M. Paula AU - Fabiane G. M. Rego AU - Dalila L. Zanette AU - Mateus N. Aoki AU - Jeanine M. Nardin AU - Luciano F. Huergo Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/23/2021.12.22.21268286.abstract N2 - Immunological assays to detect SARS-CoV-2 Spike receptor binding domain antigen seroconversion in humans are important tools to monitor the levels of protecting antibodies in the population in response to infection and/or immunization. Here we describe a simple, low cost and high throughput Ni2+ magnetic bead immunoassay to detect human IgG reactive to Spike S1 RBD Receptor Binding Domain produced in Escherichia coli. A 6xHis tagged Spike S1 RBD was expressed in E. coli and purified by affinity chromatography. The protein was mobilized on the surface of Ni2+ magnetic beads and used to investigate the presence of reactive IgG in the serum obtained from pre-pandemic and COVID-19 confirmed cases. The method was validated with a cohort of 290 samples and an area under the receiver operating characteristics curve of 0.94 was obtained. The method operated with&gt;82% sensitivity at 98% specificity and was also able to track human IgG raised in response to vaccination with Comirnaty with 85% sensitivity. The IgG signal obtained with the described method was well correlated with the signal obtained when pre fusion Spike produced in HEK cell lines were used as antigen. This novel low-cost and high throughput immunoassay may act as an important tool to investigate protecting IgG antibodies against SARS-CoV-2 in the human population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Alexander von Humboldt foundation, UFPR, CNPq, CAPES and by the Fundacao Araucaria.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Ethics Review Board CEP/HEG (n# 31592620.4.1001.0098 and n# 54095221.0.0000.0098), CEP/UFPR (n# 43948621.7.0000.0102 and n# 35872520.8.0000.0102) approved this studyI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -